Hamlet BioPharma Holds Successful In Person Meeting with US FDA
LUND, Sweden, June 25, 2025 /PRNewswire/ -- Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, today announces the successful first in-person meeting with the U.S. Food and Drug Administration (FDA). The meeting was held on June 24, 2025. The 'take home message' from the discussion was a clear pathway to the Phase III trial leading to market approval.
The Hamlet team summarized the scientific and clinical background and presented data from Hamlet's successful and recently completed Phase II study (Dec 2024). The impressive data to date in the Alpha1H program was well received by the FDA and the fruitful discussion included the clinical team in Prague and Target Health's regulatory expertise and leadership.
The discussion proceeded to cover FDA's helpful feedback on a new Phase III trial design for NMIBC patients, which will support the registration of Alpha1H. Hamlet BioPharma will now incorporate FDA's input into its Phase III protocol. The company remains on track to initiate the Phase III trial, subject to final protocol agreement and regulatory clearance. The meeting marked a key milestone in the regulatory pathway and provided an opportunity to align with the FDA on key aspects of the trial design.
`'Congratulations to the Hamlet team,'' says Adam Harris, MM, RAC, from Target Health, who was regulatory lead for the meeting with the FDA.
"We appreciate the FDA's engagement and valuable feedback as we continue the late-stage development of Alpha 1H and the treatment of Bladder Cancer," comments Catharina Svanborg, CEO, Hamlet Biopharma. "This meeting brings us one step closer to delivering a new treatment option for patients facing bladder cancer."
CONTACT:
Catharina Svanborg, CEO, Hamlet BioPharma AB, +46 709 42 65 49, [email protected]
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
PR Hamlet Biopharma.250625 |
SOURCE Hamlet BioPharma AB (publ)
Share this article